New hope for hard-to-treat lung cancer: combo therapy enters phase 2 trial
Disease control
Recruiting now
This study tests a new drug called nelmastobart combined with the chemotherapy docetaxel in people with advanced non-small cell lung cancer whose cancer has stopped responding to or cannot tolerate standard platinum-based chemo or immunotherapy. About 62 participants will receive…
Phase: PHASE2 • Sponsor: STCube, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC